Corbus Pharmaceuticals (CRBP) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, gaining 23.2% versus a loss of 60.7%. Over five years, CRBP leads with a -82.8% price change compared with -98.3% for KZIA. Corbus Pharmaceuticals is the larger company by market cap ($104.1 million vs $102.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | KZIA |
|---|---|---|
| Share price | $5.38 | $8.93 |
| Market cap | $104.06M | $102.04M |
| 1-day change | +2.09% | +1.25% |
| YTD return | -35.26% | +28.01% |
| 1-year return | -60.73% | +23.18% |
| 5-year return | -82.78% | -98.32% |
| EPS (TTM) | $-6.11 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $17.40 |
| 52-week low | $5.13 | $4.86 |
| Distance from 52-week high | -73.83% | -48.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +532.53% | +216.46% |
| Average volume | 756.54K | 262.41K |
| Shares outstanding | 19.34M | 11.43M |
| Employees | 36 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed CRBP by 83.9 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
CRBP vs KZIA FAQ
Which is bigger, Corbus Pharmaceuticals or Kazia Therapeutics?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $104.06M compared with $102.04M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, CRBP or KZIA?
KZIA returned +23.18% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.